Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06948747 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT06948747 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 49 participants.
The verdict
NCT06948747, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
This study will assess the effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the effect of Erythromycin on AZD5004 in healthy adult male and female participants.
Interventions
- DRUG Rosuvastatin
- DRUG Erythromycin
- DRUG Simvastatin
- DRUG AZD5004
- DRUG Atorvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2025-05-06 |
| Est. Completion | 2025-10-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06948747
The ClinicalTrials.gov registry entry for NCT06948747 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Rosuvastatin is the first listed.
NCT06948747 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06948747 about?
NCT06948747 is a clinical study titled "A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants". This study will assess the effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the effect of Erythromycin on AZD5004 in healthy adult male and female participants.
What is the current status of trial NCT06948747?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2025-05-06. Estimated completion is 2025-10-03.
What interventions are being tested in trial NCT06948747?
The interventions under investigation include: Rosuvastatin (DRUG), Erythromycin (DRUG), Simvastatin (DRUG), AZD5004 (DRUG), Atorvastatin (DRUG).
Who is sponsoring clinical trial NCT06948747?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.